{"id":626673,"date":"2022-11-22T15:18:01","date_gmt":"2022-11-22T15:18:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=626673"},"modified":"2022-11-22T15:18:01","modified_gmt":"2022-11-22T15:18:01","slug":"musculoskeletal-pain-market-to-witness-growth-by-20222032-estimates-delveinsight-key-companies-mesoblast-regenron-teva-taiwan-liposome-eli-lilly-axsome-therapeutics","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/musculoskeletal-pain-market-to-witness-growth-by-20222032-estimates-delveinsight-key-companies-mesoblast-regenron-teva-taiwan-liposome-eli-lilly-axsome-therapeutics_626673.html","title":{"rendered":"Musculoskeletal pain Market to Witness Growth by (2022-2032), Estimates DelveInsight | Key Companies &#8211; Mesoblast, Regenron, Teva, Taiwan Liposome, Eli Lilly, Axsome Therapeutics"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1669116830.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Musculoskeletal pain Market to Witness Growth by (2022-2032), Estimates DelveInsight | Key Companies - Mesoblast, Regenron, Teva, Taiwan Liposome, Eli Lilly, Axsome Therapeutics\" src=\"https:\/\/www.abnewswire.com\/uploads\/1669116830.jpeg\" alt=\"Musculoskeletal pain Market to Witness Growth by (2022-2032), Estimates DelveInsight | Key Companies - Mesoblast, Regenron, Teva, Taiwan Liposome, Eli Lilly, Axsome Therapeutics\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">The Musculoskeletal pain market is expected to surge due to the disease&#8217;s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Musculoskeletal pain pipeline products will significantly revolutionize the Musculoskeletal pain market dynamics.<\/div>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s <strong>&ldquo;Musculoskeletal pain Market Insights, Epidemiology, and Market Forecast-2032&Prime;<\/strong> report offers an in-depth understanding of the Musculoskeletal pain, historical and forecasted epidemiology as well as the Musculoskeletal pain market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">The Musculoskeletal pain market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current &amp; forecasted market size from 2019 to 2032. It also evaluates the current treatment practice\/algorithm, market drivers &amp; barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>To Know in detail about the Musculoskeletal pain market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/musculoskeletal-pain-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Musculoskeletal pain Market Insights<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Musculoskeletal pain Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Musculoskeletal pain is defined as acute or chronic pain that affects bones, muscles, ligaments, tendons, and even nerves, and the pain associated with musculoskeletal (MSK) disorders is a common medical and socioeconomic problem worldwide.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of the key facts of the Musculoskeletal pain Market Report:&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The Musculoskeletal pain market size was valued at <strong>USD 3,647.2 Million<\/strong> in the year 2021 and is anticipated to grow with a significant <strong>CAGR<\/strong> during the study period <strong>(2019-2032)<\/strong><\/li>\n<li>The total 7MM diagnosed prevalent cases of musculoskeletal pain in 2020 were <strong>145,426,730 cases<\/strong><\/li>\n<li>Among the 7MM countries the highest prevalence of Musculoskeletal pain were observed in the United States<\/li>\n<li>In 2020, there were <strong>76,331,935<\/strong> diagnosed prevalent cases of musculoskeletal pain in the United States<\/li>\n<li><strong>Key Musculoskeletal pain Companies:<\/strong> Mesoblast, Regenron, Teva, Taiwan Liposome, Eli Lilly, Axsome Therapeutics, Biosplice Therapeutics, Centrexion Therapeutics, Techfields Pharma, and others<\/li>\n<li><strong>Key Musculoskeletal pain Therapies:<\/strong> MPC-06-ID, Fasinumab, TLC599, Eli Lilly, AXS-14, Lorecivivint, CNTX-4975, X0002, and others<\/li>\n<li>The musculoskeletal pain epidemiology based on gender analyzed that in the United States, musculoskeletal pain is more prevalent in females than in males<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Get a Free sample for the Musculoskeletal pain Market Report&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/musculoskeletal-pain-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">https:\/\/www.delveinsight.com\/sample-request\/musculoskeletal-pain-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Key benefits of the Musculoskeletal pain Market report:<\/strong><\/p>\n<ol style=\"text-align: justify;\" start=\"1\">\n<li>Musculoskeletal pain market report covers a descriptive overview and comprehensive insight of the Musculoskeletal pain Epidemiology and Musculoskeletal pain market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) &amp; Japan.)<\/li>\n<li>The Musculoskeletal pain market report provides insights on the current and emerging therapies.<\/li>\n<li>Musculoskeletal pain market report provides a global historical and forecasted market covering drug outreach in 7MM.<\/li>\n<li>The Musculoskeletal pain market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Musculoskeletal pain market.<\/li>\n<\/ol>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Download the report to understand which factors are driving Musculoskeletal pain epidemiology trends @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/musculoskeletal-pain-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Musculoskeletal pain Epidemiological Insights<\/a>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Musculoskeletal pain Market<\/strong> &nbsp;<\/p>\n<p style=\"text-align: justify;\">The dynamics of the Musculoskeletal pain market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032. &nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Musculoskeletal pain Epidemiology<\/strong><\/p>\n<p style=\"text-align: justify;\">The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Musculoskeletal pain Epidemiology Segmentation:<\/strong><\/p>\n<p style=\"text-align: justify;\">The Musculoskeletal pain market report proffers epidemiological analysis for the study period 2019&ndash;2032 in the 7MM segmented into:<\/p>\n<ul style=\"text-align: justify;\">\n<li>Total Prevalence of Musculoskeletal pain<\/li>\n<li>Prevalent Cases of Musculoskeletal pain by severity<\/li>\n<li>Gender-specific Prevalence of Musculoskeletal pain<\/li>\n<li>Diagnosed Cases of Episodic and Chronic Musculoskeletal pain<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Musculoskeletal pain Drugs Uptake and Pipeline Development Activities<\/strong><\/p>\n<p style=\"text-align: justify;\">The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Musculoskeletal pain market or expected to get launched during the study period. The analysis covers Musculoskeletal pain market uptake by drugs, patient uptake by therapies, and sales of each drug.&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\">Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.<\/p>\n<p style=\"text-align: justify;\">The report also covers the Musculoskeletal pain Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Discover more about therapies set to grab major Musculoskeletal pain market share @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/musculoskeletal-pain-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Musculoskeletal pain market forecast&nbsp;<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Musculoskeletal pain Therapies and Key Companies<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>MPC-06-ID:<\/strong> Mesoblast<\/li>\n<li><strong>Fasinumab:<\/strong> Regenron\/Teva<\/li>\n<li><strong>TLC599:<\/strong> Taiwan Liposome<\/li>\n<li><strong>LY3016859:<\/strong> Eli Lilly<\/li>\n<li><strong>AXS-14:<\/strong> Axsome Therapeutics<\/li>\n<li><strong>Lorecivivint:<\/strong> Biosplice Therapeutics<\/li>\n<li><strong>CNTX-4975:<\/strong> Centrexion Therapeutics<\/li>\n<li><strong>X0002:<\/strong> Techfields Pharma<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Musculoskeletal pain Market Drivers<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Robust Musculoskeletal pain pipeline<\/li>\n<li>Long-term cure<\/li>\n<li>Increasing Musculoskeletal pain prevalence<\/li>\n<li>Increase in Musculoskeletal pain awareness<\/li>\n<li>Multidisciplinary approach<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Musculoskeletal pain Market Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Study Period: 2019&ndash;2032<\/strong><\/li>\n<li><strong>Coverage:<\/strong> 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]<\/li>\n<li><strong>Key Musculoskeletal pain Companies:<\/strong> Mesoblast, Regenron, Teva, Taiwan Liposome, Eli Lilly, Axsome Therapeutics, Biosplice Therapeutics, Centrexion Therapeutics, Techfields Pharma, and others<\/li>\n<li><strong>Key Musculoskeletal pain Therapies:<\/strong> MPC-06-ID, Fasinumab, TLC599, Eli Lilly, AXS-14, Lorecivivint, CNTX-4975, X0002, and others<\/li>\n<li><strong>Musculoskeletal pain Therapeutic Assessment:<\/strong> Musculoskeletal pain current marketed and Musculoskeletal pain emerging therapies<\/li>\n<li><strong>Musculoskeletal pain Market Dynamics:&nbsp;<\/strong>Musculoskeletal pain market drivers and Musculoskeletal pain market barriers&nbsp;<\/li>\n<li><strong>Competitive Intelligence Analysis:<\/strong> SWOT analysis, PESTLE analysis, Porter&rsquo;s five forces, BCG Matrix, Market entry strategies<\/li>\n<li><strong>Musculoskeletal pain Unmet Needs, KOL&rsquo;s views, Analyst&rsquo;s views, Musculoskeletal pain Market Access and Reimbursement&nbsp;<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Musculoskeletal pain Market Barriers<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Off-label drugs usage<\/li>\n<li>Unspecific assessment<\/li>\n<li>Misclassification<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Musculoskeletal pain Market Report Introduction<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary for Musculoskeletal pain<\/p>\n<p style=\"text-align: justify;\">3. SWOT analysis of Musculoskeletal pain<\/p>\n<p style=\"text-align: justify;\">4. Musculoskeletal pain Patient Share (%) Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">5. Musculoskeletal pain Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">6. Musculoskeletal pain Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\">7. Musculoskeletal pain Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\">8. Country-Specific Patient Population of Musculoskeletal pain&nbsp;<\/p>\n<p style=\"text-align: justify;\">9. Musculoskeletal pain Current Treatment and Medical Practices<\/p>\n<p style=\"text-align: justify;\">10. Musculoskeletal pain Unmet Needs<\/p>\n<p style=\"text-align: justify;\">11. Musculoskeletal pain Emerging Therapies<\/p>\n<p style=\"text-align: justify;\">12. Musculoskeletal pain Market Outlook<\/p>\n<p style=\"text-align: justify;\">13. Country-Wise Musculoskeletal pain Market Analysis (2019&ndash;2032)<\/p>\n<p style=\"text-align: justify;\">14. Musculoskeletal pain Market Access and Reimbursement of Therapies<\/p>\n<p style=\"text-align: justify;\">15. Musculoskeletal pain Market Drivers<\/p>\n<p style=\"text-align: justify;\">16. Musculoskeletal pain Market Barriers<\/p>\n<p style=\"text-align: justify;\">17.&nbsp; Musculoskeletal pain Appendix<\/p>\n<p style=\"text-align: justify;\">18. Musculoskeletal pain Report Methodology<\/p>\n<p style=\"text-align: justify;\">19. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\">20. Disclaimer<\/p>\n<p style=\"text-align: justify;\">21. About DelveInsight<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>To know more about Musculoskeletal pain treatment, visit @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/musculoskeletal-pain-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Musculoskeletal pain Medications<\/a>&nbsp;<\/strong><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_75707.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Gaurav Bora<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=musculoskeletal-pain-market-to-witness-growth-by-20222032-estimates-delveinsight-key-companies-mesoblast-regenron-teva-taiwan-liposome-eli-lilly-axsome-therapeutics\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=musculoskeletal-pain-market-to-witness-growth-by-20222032-estimates-delveinsight-key-companies-mesoblast-regenron-teva-taiwan-liposome-eli-lilly-axsome-therapeutics\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The Musculoskeletal pain market is expected to surge due to the disease&#8217;s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Musculoskeletal pain pipeline products will significantly revolutionize the Musculoskeletal pain market dynamics. DelveInsight&rsquo;s &ldquo;Musculoskeletal pain Market &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/musculoskeletal-pain-market-to-witness-growth-by-20222032-estimates-delveinsight-key-companies-mesoblast-regenron-teva-taiwan-liposome-eli-lilly-axsome-therapeutics_626673.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-626673","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/626673","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=626673"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/626673\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=626673"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=626673"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=626673"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}